Back to Results
First PageMeta Content
Medicine / Monoclonal antibodies / Immune system / Etanercept / Rheumatoid arthritis / Adalimumab / Regeneron / Disease-modifying antirheumatic drug / Tocilizumab / Immunosuppressants / Pharmacology / Immunology


Document Date: 2015-03-12 09:25:34

Open Document

File Size: 36,06 KB

Share Result on Facebook

City

Tarrytown / New York / Paris / /

Company

TARGET / Genzyme / Regeneron Pharmaceuticals Inc. / Sanofi / Regeneron Laboratories / /

Country

France / /

/

Event

Product Issues / Company Listing Change / FDA Phase / /

Facility

Stanford University / /

IndustryTerm

healthcare / antibody technology / therapeutic solutions / consumer healthcare / science-based biopharmaceutical / diabetes solutions / /

MedicalCondition

moderate-to-severe rheumatoid arthritis / atopic dermatitis / colorectal cancer / inflammatory process / leukopenia / Rheumatoid Arthritis / tumor necrosis factor alpha / rare inflammatory condition / Rheumatoid Arthritis Rheumatoid arthritis / moderateto-severe rheumatoid arthritis / asthma / resultant cytokine-mediated inflammatory signaling cascade / disease / diabetes / active disease / autoimmune disease / eye diseases / anemia / hypercholesterolemia / RA-related inflammation / /

Organization

Division of Immunology and Rheumatology / Stanford University / FDA / /

Person

Manisha Narasimhan / George D. Yancopoulos / Mark Genovese / Jorge Insuasty / Marisol Péron / Sébastien Martel / Sandy Sexton / /

/

Position

President / active-calibrator / Vice President / Global R&D and Deputy / Chief Scientific Officer / President for Development / integrated global healthcare leader / Private / Professor of Medicine / /

Product

Sarilumab / IL6R / response / /

ProvinceOrState

New York / /

SportsLeague

Stanford University / /

Technology

alpha / therapeutic solutions / antibody technology / /

URL

www.regeneron.com / /

SocialTag